Medication and diabetic complications

Automated insulin delivery reduces hypoglycemia in people with type 1 diabetes at increased risk, improving their time spent in target glucose range.

Result from ONWARDS 5 trial show weekly insulin icodec plus a dosing app offers greater reductions in glycated hemoglobin than daily basal insulin analogs for type 2 diabetes.

A retrospective analysis has found a significantly higher incidence of hyperglycemia among breast cancer patients treated with alpelisib in standard care than on clinical trials.

Novel model for risk prediction of kidney disease progression and efficacy of SGLT2 inhibition in patients with type 2 diabetes.

SGLT2 inhibitors and GLP-1 receptor agonists appear to offer the best protection against major adverse cardiovascular events in people with type 2 diabetes.

Finerenone modifies the risk for chronic kidney disease associated cardiovascular events in patients with type 2 diabetes and moderate-to-severe albuminuria, FIDELITY study findings indicate.

Different antidiabetic medications commonly used in addition to metformin for type 2 diabetes have a similar effect on kidney function.

The results of ONWARDS 2 show significantly improved glycemic control with weekly insulin icodec versus daily insulin degludec, without significantly increased hypoglycemia, in people with type 2 diabetes.

A post-hoc analysis of DAPA-CKD indicates that people taking dapagliflozin have a reduced risk for hospitalization, for causes not limited to cardiac or renal.

A meta-analysis published in The Lancet supports the use of SGLT2 inhibitors in people with chronic kidney disease, irrespective of whether they have type 2 diabetes.

Treating people with chronic kidney disease with the SGLT2 inhibitor empagliflozin significantly reduces their risk for renal disease progression or cardiovascular mortality, report the EMPA-KIDNEY investigators.

SGLT2 inhibitors are associated with a lower risk for gout than DPP-4 inhibitors, research suggests.

People taking basal insulin to treat type 2 diabetes experience a significant reduction in the risk for acute complications, which is sustained for at least 2 years after initiating use of the Freestyle Libre, say French researchers.

Pooled analysis of FIDELIO-DKD and FIGARO-DKD suggests that people with type 2 diabetes and chronic kidney disease benefit from finerenone irrespective of whether they are also using an SGLT2 inhibitor.

Starting people on bevacizumab and switching to aflibercept only when necessary keeps costs down without compromising treatment efficacy for people with diabetic macular edema, shows a randomized trial.

The SGLT1/2 inhibitor licogliflozin has reduced liver enzyme levels in people with nonalcoholic steatohepatitis in a phase 2 trial published in Nature Medicine.

People with type 2 diabetes have a lower risk for chronic kidney disease progression and death when using SGLT2 inhibitors than when given DPP-4 inhibitors, real-world study data show.

Switching 1% of standard bolus insulin lispro to a liver-targeted formulation decreases hypoglycemic events without affecting glucose control, OPTI-1 study findings indicate.

The ADA and KDIGO have produced a consensus statement on treating chronic kidney disease in people with diabetes.

The risk for hypoglycemia from an accidental basal insulin overdose is no higher with weekly insulin icodec than with daily glargine U100 in people with type 2 diabetes, report researchers.